Trends and challenges in the Pharma and Life Science Industry

High turnover is a significant issue in the life sciences industry, driven by factors such as competitive job markets, burnout from high-pressure roles, and limited career advancement opportunities. Compliance with varying international regulations is crucial, as is finding candidates who can adapt to global standards while bringing local expertise. These regulations influence who is available, who is qualified, and ultimately, who can drive the innovation that the life sciences industry depends on. Whether it's FDA guidelines in the U.S. or EMA regulations in Europe, the complexity of global compliance demands a workforce that can navigate these challenges with precision. AI-driven insight and decision support for LabVantage CORTEX workflows while preserving the validated system of By addressing the skills gap, the life sciences industry can maintain its trajectory of groundbreaking innovation and improve global health outcomes.

• “With every incremental improvement, we can potentially decrease timelines and increase success rate, bringing therapies to more patients in need.”
• Although there has been a downturn in M&A activities over the past decade, life sciences companies are poised to witness an increase in M&A values in 2023 due to increased competition and the growing demand for multi-indication pharmaceutical products.
• The skills gap in life sciences refers to the difference between the specialized expertise that organizations require and the current capabilities of the workforce.
• We can help clients optimize business continuity and disaster recovery capabilities by managing redundant systems and off-site data backup capabilities and develop clear processes and protocols for communicating an event and preparing for an extended downtime while also working to restore critical operations and capabilities.
• Successful companies will differentiate themselves in the market by offering digital support for their pharmaceuticals, engaging patients in their care on their smartphones through gamification and incentive programs.
• In addition to making sure they stay current on this fast-moving field, CEOs and top management at life sciences companies must encourage the implementation of processes that can mitigate bias, using best practices published by Google AI and other resources.8

Companies must evaluate their vendors' technical expertise and experience with life sciences best practices to drive successful project outcomes. Proper planning is essential for maintaining validated states and ensuring ongoing regulatory compliance with frequent cloud updates. The pharma and life sciences industry is undergoing rapid transformation, driven by technology, patient-centric models, sustainability and evolving regulatory demands. These regulations are implemented to ensure product safety, efficacy, and reliability.

AI is changing every aspect of the life sciences industry. Shukla’s recent research has focused on the future of health, AI and digital transformation, and financial transformation. US health care leaders are optimistic about 2025, focusing on growth, profitability, and consumer affordability amid evolving regulations and technological advancements Discover how AI, workforce shifts, and new care models are transforming health care. BioIndustry Association – Skills and workforce forecast for the UK life sciences sector Whether you manage drug development pipelines, call therapy programs, or multi-site clinical portfolios, Cora gives your teams the visibility and control to execute at scale.

Diversifying Capital Raising Strategies

Cora provides real-time visibility into resource capacity, demand, and skills, allowing leaders to prioritise critical programs and prevent over-allocation. Adoption-first approaches — focused on clarity, usability, and alignment with how people work — are becoming just as important as compliance itself. Governance and compliance pressures continue to rise across life sciences, driven by tighter regulations, faster innovation cycles, and more global operating models.

As DCTs are more broadly adopted, designing trials around the patient experience will be critical to ensuring clear, transparent engagement and willing and active participation. Life sciences organizations will increase their use of DCTs to run global studies and bring new therapies to market. NGS will become more mainstream, moving the science out of the lab to deliver improved patient care and outcomes at scale. These therapies will challenge life sciences organizations to rethink their business models. According to the Alliance for Regenerative Medicine, we could see five more gene therapies for rare diseases introduced to the U.S. market in 2023, including new treatments for sickle cell disease, Duchenne muscular dystrophy and hemophilia.

This scarcity of talent can lead to increased labor rates, impacting a company’s overall cost structure and profitability, and reduced productivity. For life sciences companies, developing and investing in sustainable solutions for your products, services, and facilities can help you meet this demand — and comply with increasingly stringent regulations. This scarcity of talent can lead to increased labor rates, impacting your company’s overall cost structure and profitability, and reduced productivity. What follows are 10 critical factors currently putting life sciences companies through their paces as they strive to confront today’s industry realities. Retaining top talent requires offering competitive compensation, clear career advancement opportunities, and fostering a supportive work environment. Life sciences companies must adopt tailored recruitment strategies that align with these challenges to secure the top talent necessary for future success.

Tune in to hear how retailers are building resilience and improving decision-making when uncertainty becomes the norm. BDO's integrated approach to risk management helps companies focus on their success while enabling effective strategies to navigate the challenges they face and protect human health, private data and information, and the organization itself. Accessing, synthesizing, and assessing data for market analytics, labor analytics, compliance requirements, or financial reporting is no longer a competitive advantage. challenges in life sciences industry There are numerous stakeholders and audiences that have a variety of expectations including markets seeking financial information, regulatory filings, quality, and safety. Life sciences has exposure to multiple vulnerabilities including distributed and decentralized production; research and development; supply chain dependencies with multiple partners and vendors; aged systems; sensitive data on clinical patients, personnel, formulations; and intellectual property that are highly valuable targets for corporate espionage and ransomware attacks. Life science leaders are under pressure to perform in the face of increasingly complex and potentially catastrophic risks to financial performance and reporting, capital allocation and working capital, product quality, human safety, market and product competition, pricing and margin, and intellectual property.

Attracting and retaining top talent requires creating a supportive work environment. Additionally, with new reimbursement models, payers incentivize “complete” cases that achieve prolonged remission or, for acute patients, functional recovery. Increased scrutiny by public authorities, along with COVID-19, disrupted a traditional approach where sales reps had HCP offices and hospitals as their second home. Achieving full value from AI requires transformation of the discovery process spanning new tech, new talent and new behaviors throughout the R&D organization. The first AI-designed drug candidate to enter clinical trials was reported by Exscientia in early 2020.

It focuses on targeting a person’s genes for modification to treat or cure disease, including cancer, genetic diseases and infectious diseases. Leading companies will invest in AI, ML and intelligent workflows to deliver end-to-end forecasting capabilities that utilize real-time feeds from multiple data sources, leveraging hundreds of AI and ML models, to deliver more granular and accurate forecasts and customer insights. Pharma will focus on digital patient recruitment through social advertising and digital engagement (including wearables) throughout trials to manage adherence and persistence. The cost of active pharmaceutical ingredients has increased by up to 70% since 2018. By adopting risk-based approaches, organizations can focus on real-world, critical testing while reducing the burden of excessive documentation.